Skip to content
Screener

Vertex Pharmaceuticals VRTX Q4 2025 Annual earnings

Reported February 12, 2026 · After market close

Revenue$3.2BBeat by $5.8M
EPS$5.03Miss by $0.08
Revenue estimate$3.2B
EPS estimate$5.11

Next report

Nov 2, 2026 (in a month)
Revenue estimate$3.4B
EPS estimate$4.76

Financials

Q4 2025

Income statement

See full
Revenue$3.2B+9.5%
Gross profit$2.7B+9.5%
Operating income$1.2B—
Net income$1.2B—
EPS (diluted)$4.64—

Balance sheet

See full
Cash & equivalents$5.1B+11.3%
Total debt$2.0B+16.4%
Total equity$18.7B+13.7%
Total assets$25.6B+13.8%

Cash flow

See full
Operating cash flow$498.0M+504%
CapEx$149.4M+61.3%
Free cash flow$348.6M+276%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$115.03B+10.9%
Enterprise value$111.97B+11.0%
P/E29.1×—
P/S9.6×+0.2×

Profitability

See full
Gross margin86.2%+0.1pp
Operating margin34.8%—
Net margin32.9%—
FCF margin26.6%+17.7pp

Returns & leverage

See full
Return on equity22.5%—
Debt / equity0.1×0.0×
Current ratio2.9×+0.2×

Segments

By product

See full
TRIKAFTA/KAFTRIO$2.6B-5.5%
ALYFTREK$380.1M—
Other CF product revenues$237.4M+24.2%

By segment

See full
Pharmaceuticals$3.2B+9.5%

FAQ

When did Vertex Pharmaceuticals report Q4 2025 earnings?
Vertex Pharmaceuticals (VRTX) reported Q4 2025 earnings on February 12, 2026 after market close.
What were Vertex Pharmaceuticals's Q4 2025 revenue and EPS?
Vertex Pharmaceuticals reported revenue of $3.2B and eps of $5.03 for Q4 2025.
Did Vertex Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $3.2B by $5.8M. EPS missed the consensus estimate of $5.11 by $0.08.
How did Vertex Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.5% from $2.9B a year earlier and eps grew 26.4% from $3.98.
Where can I find Vertex Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000875320-26-000034) and the 10-K periodic report (0000875320-26-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.